CatalYm
Catalyzing Immunotherapy
Planegg-Martinsried, Germany · Founded 2016 · $216.0M raised
- Headquarters
- Planegg-Martinsried
- Founded
- 2016
- Business Model
- B2B
- Website
- catalym.com
- Total Funding
- $216.0M
- Last Round
- $150.0M Series DJul 2024
- Rounds
- 2
About
CatalYm is a clinical-stage biotech company focused on neutralizing GDF-15, a key cancer immunosuppressant hijacked by tumors to evade immune attack. Its lead antibody visugromab has demonstrated durable anti-tumor efficacy in combination with anti-PD-1 in relapsed and refractory metastatic solid tumor patients. Founded in 2016, CatalYm is headquartered in Planegg-Martinsried (Munich), Germany, and advancing visugromab into Phase 2b studies.
Summary
CatalYm is a Biotech company based in Planegg-Martinsried, Germany, founded in 2016. It has raised $216.0M in total across 2 rounds, most recently a $150.0M Series D round in Jul 2024. Investors include Canaan Partners, Bioqube Ventures and Forbion Growth Opportunities Fund.
Tech & App Stack
3 technologies & apps tracked
Create a free account to track companies, build lists, and unlock premium data like the full tech & app stack.
Sign up to view funding chart
Create a free account to see funding visualizations and detailed round data.
Funding History
Jul 2024
Sign up to see all 2 rounds
Full funding history, per-round amounts, and investor participation.
Investors
Similar Companies
Global contract research organization providing comprehensive drug development and laboratory ser...
Global fertility clinics platform
Biopharmaceutical services company
Specialty pharmaceutical company
Biotech advancing cellular rejuvenation programming to restore cell health and reverse disease.
Global oncology biopharmaceutical company developing and commercializing cancer treatments, now r...